Get used to the approvals for more and more indications. 1 right after the other. The MOA and patient specific nature of this treatment means it's the right target(s) for the right patients regardless of tumor location every time. L validates Direct and Direct is DC VaxL amplified and improved.
They are validating the long term survival in this trial which will pay dividends as it sets precedent for future indications.
SG from the FDA just alluded to a shift with the FDA in his most recent presentation regarding approving treatments based on genetic makeup over tumor location. Ponder that for a moment.
News 
Market Data 
Discover 
